By Katherine Hamilton
Shares of BioAge Labs were higher after the company shared positive data for a trial of its drug as a treatment for inflammation.
The stock gained 9% to $20.49 in pre-market trading Tuesday. Through Monday's close, shares were up 42% this year.
In a Phase 1 clinical trial, the drug BGE-102 achieved potential best-in-class reductions in high-sensitivity C-reactive protein, a test of inflammation levels and cardiovascular risk.
Patients dosed with 60 milligrams achieved reductions that were comparable to those who received a higher dose of 120 milligrams, the biopharmaceutical company said.
Based on the results, BioAge plans to start a dose-ranging Phase 2 trial studying the drug as a treatment for cardiovascular risk. It intends to initiate the trial in the first half of 2026, with data anticipated in the second half of the year.
Write to Katherine Hamilton at katherine.hamilton@wsj.com
(END) Dow Jones Newswires
April 21, 2026 07:58 ET (11:58 GMT)
Copyright (c) 2026 Dow Jones & Company, Inc.